Skip to main content
Premium Trial:

Request an Annual Quote

Ann Hanham

HTG Molecular Diagnostics has appointed Ann Hanham to its board of directors. Hanham is a founding and managing partner of BAR Capital Management. She currently serves on two other public company boards, and has served on the boards of 20 global companies, both private and public. From February 2000 to November 2013, she served as managing director and general partner of Burrill & Company.  Prior to that, Hanham held positions in clinical and regulatory affairs, and product development at various companies, including InterMune, Otsuka America Pharmaceuticals, Celtrix Pharmaceuticals, and Becton Dickinson.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.